文献速递肿瘤 PET/CT

非小细胞肺癌患者中[18F]阿法替尼PET/CT定量可行性研究

Quantification of [18F]afatinib using PET/CT in NSCLC patients: a feasibility study.
PubMed 文献 · EJNMMI Res · 2020-08-17

该研究在10例非小细胞肺癌(NSCLC)患者中行[18F]阿法替尼动态PET/CT,评估血浆输入模型与简化定量方法。基于AIC,肿瘤动力学最佳描述为不可逆两组织室模型(2T3K_vb)联合代谢物校正采样器输入函数,TBR60-90与模型相关性极好,且肿瘤摄取不依赖灌注。

要点

  • [18F]阿法替尼PET/CT定量首选2T3K_vb模型联合代谢物校正采样器输入函数。
  • TBR60-90是与2T3K_vb模型相关性最佳的简化定量参数。
  • 肿瘤[18F]阿法替尼摄取不依赖灌注。

核心结论

  • NSCLC肿瘤[18F]阿法替尼摄取定量的首选药代动力学模型为2T3K_vb模型。
  • TBR60-90与该模型相关性极好,是最佳简化方法候选。

研究设计与样本

  • 在10例NSCLC患者中行[18F]阿法替尼PET扫描,首例用于剂量测定。
  • 后续患者先行20分钟动态[15O]H2O PET(370 MBq),再行动态[18F]阿法替尼PET(342±24 MBq)60或90分钟。
  • 采用AIC评估三种药代动力学血浆输入模型,分别联合代谢物校正采样器输入函数和图像衍生输入函数(IDIF)加离散血样。
  • 分析动脉在线采样与IDIF的相关性,并评估灌注依赖性与简化测量。

主要发现

  • 共纳入10例患者,[18F]阿法替尼注射活度为341±37 MBq。
  • 扫描视野内可识别15个肿瘤。
  • 基于AIC,肿瘤动力学最佳描述为不可逆两组织室模型联合代谢物校正采样器输入函数(Akaike 50%)。
  • 血浆输入函数与代谢物校正IDIF相关性很强(r2=0.93)。
  • 肿瘤[18F]阿法替尼摄取不依赖灌注。

关键数值与推荐

  • 首选简化摄取参数为60至90分钟时间间隔的肿瘤与血比值(TBR60-90)。
  • 最佳药代动力学模型为2T3K_vb模型。

临床怎么用

  • 可采用TBR60-90作为[18F]阿法替尼PET定量NSCLC肿瘤摄取的简化参数。
  • 若需完整定量,可选用2T3K_vb模型联合代谢物校正采样器输入函数。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Only a subgroup of non-small cell lung cancer (NSCLC) patients benefit from treatment using epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) such as afatinib. Tumour uptake of [18F]afatinib using positron emission tomography (PET) may identify those patients that respond to afatinib therapy. Therefore, the aim of this study was to find the optimal tracer kinetic model for quantification of [18F]afatinib uptake in NSCLC tumours. METHODS: [18F]Afatinib PET scans were performed in 10 NSCLC patients. The first patient was scanned for the purpose of dosimetry. Subsequent patients underwent a 20-min dynamic [15O]H2O PET scan (370 MBq) followed by a dynamic [18F]afatinib PET scan (342 ± 24 MBq) of 60 or 90 min. Using the Akaike information criterion (AIC), three pharmacokinetic plasma input models were evaluated with both metabolite-corrected sampler-based input and image-derived (IDIF) input functions in combination with discrete blood samples. Correlation analysis of arterial on-line sampling versus IDIF was performed. In addition, perfusion dependency and simplified measures were assessed. RESULTS: Ten patients were included. The injected activity of [18F]afatinib was 341 ± 37 MBq. Fifteen tumours could be identified in the field of view of the scanner. Based on AIC, tumour kinetics were best described using an irreversible two-tissue compartment model and a metabolite-corrected sampler-based input function (Akaike 50%). Correlation of plasma-based input functions with metabolite-corrected IDIF was very strong (r2 = 0.93). The preferred simplified uptake parameter was the tumour-to-blood ratio over the 60- to 90-min time interval (TBR60-90). Tumour uptake of [18F]afatinib was independent of perfusion. CONCLUSION: The preferred pharmacokinetic model for quantifying [18F]afatinib uptake in NSCLC tumours was the 2T3K_vb model. TBR60-90 showed excellent correlation with this model and is the best candidate simplified method. TRIAL REGISTRATION: https://eudract.ema.europa.eu/ nr 2012-002849-38.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. van de Stadt EA, Yaqub M, Lammertsma AA, et al. Quantification of [18F]afatinib using PET/CT in NSCLC patients: a feasibility study. EJNMMI Res. 2020. PMID: 32804306. doi:10.1186/s13550-020-00684-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。